Vascular and non-vascular approaches to the treatment of stroke

Bibliography

• TAYLOR TN, DAVIS PH, TORNER JC, et al. Lifetime cost of stroke in the United States. Stroke (1996) 27:1459–1466.
   PubMed Web of Science ®Google Scholar
• Barnett HJ, Mohr JP, Stein BM, Yatsu FM (Eds.), Churchill Livingstone, New York (1992)3–27.
   Google Scholar
• FISHER M, GARCIA JH: Evolving stroke and the ischemic penumbra. Neurology (1996) 47:884–888.
   PubMed Web of Science ®Google Scholar
• JOHNSTON KC, LI JY, LYDEN PD, et al. Medical and neurological complications of ischemic stroke experience from the RANTTAS trial. Stroke (1998) 29:447–453.
   PubMed Web of Science ®Google Scholar
• ADAMS HP, BROTT TG, FURLAN AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischaemic stroke. A special writing group of the Stroke Council, American Heart Association. Stroke (1996) 27:1711–1718.
   PubMed Web of Science ®Google Scholar
• BESSON G, BOGOUSSLAVSKY J: Current and future options for the prevention and treatment of stroke. CNS Drugs (1995) 3:351–362.
   Web of Science ®Google Scholar
• RODERICK J, WILKES HC, MEADE TW: The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. J. Clin. Pharmacol. (1993) 35:219–226.
   Web of Science ®Google Scholar
• BLANDIN CF, NORRIS JW: Relative benefits of ticlopidine and aspirin. Stroke (1994) 25:2290.
   PubMed Web of Science ®Google Scholar
• GENT M, BLAKELY JA, EASTON JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 2:1215–1220.
   Google Scholar
• PICANO E, ABBRACCHIO MP: European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation Trends Pharmacol. Sci. (1998) 19:14–16.
   Google Scholar
• MASUHR F, BUSCH M, EINHAUPL KM: Differences between medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe. Stroke (1998) 29:339–345.
   PubMed Web of Science ®Google Scholar
• WARDLAW JM, WARL OW CP, COUNSELL C: Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet (1997) 350:607–614.
   PubMed Web of Science ®Google Scholar
• WANG YF, TSIRKA SE, STRICKLAND S, et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nature Med. (1998) 2:228–231.
   Google Scholar
• DEL ZOPPO GJ, WAGNER S, TAGAYA M: Trends and future developments in the pharmacological treatment of acute ischaemic stroke. Drugs (1997) 54:9–38.
   PubMed Web of Science ®Google Scholar
• LEES KR: Cerestat and other NMDA antagonists in ischemic stroke. Neurology (1997) 49:S66–S69.
   PubMed Web of Science ®Google Scholar
• MUIR KW, GROSSET DG, LEES KR: Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Clin. Neuropharmacol. (1997) 20:311–321.
   PubMed Web of Science ®Google Scholar
• ROWLEY M, KULAGOWSKI JJ, WATT AP, et al. Effect of plasma-protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem. (1997) 40:4053–4068.
   PubMed Web of Science ®Google Scholar
• PRINGLE AK, BENHAM CD, SIM L, et al. Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. Stroke (1996) 27:2124–2130.
   PubMed Web of Science ®Google Scholar
• MILIJANICH GP, RAMACHANDRAN J: Antagonists of neuronal calcium channels: structure, function and therapeutic implications. Ann. Rev. Pharmacol. Toxicol. (1995) 35:707–734.
   PubMed Web of Science ®Google Scholar
• Green AR, Cross AJ (Eds.), Academic Press (1997):95–108.
   Google Scholar
• DE VRY J, DIETRICH H, GLASER T, et al. BAY x 3702. Drugs Future (1997) 22:341–349.
   Google Scholar
• GREEN R, CROSS AJ: The neuroprotective actions of chlormethiazole. Prog. Neurobiol. (1994) 44:463–484.
   PubMed Web of Science ®Google Scholar
• CHARRIAUT-MARLANGUE C, MARGAILL I, REPRESA A, et al. Apoptosis and necrosis after reversible focal ischaemia: an in situ DNA fragmentation analysis. J. Cereb. Blood Flow Metab. (1996) 16:186–194.
   PubMed Web of Science ®Google Scholar
• HARA H, FRIEDLANDER RN, GAGLIARDINI V, et al. Inhibition of interleukin 113 converting enzyme family proteases reduces ischemic and excitoxic neuronal damage. Proc. Natl. Acad. Sci. USA (1997) 94:2007–2012.
   PubMed Web of Science ®Google Scholar
• MATTSON MP: Calcium and free radicals: mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death. Perspect. Dev. Neurobiol. (1996) 3:79–91.
   PubMedGoogle Scholar
• STRIJBOS PJ, LEACH MJ, GARTHWAITE J: Vicious cycle involving Na + channels, glutamate release and NMDA receptors mediates delayed neurodegeneration through nitric oxide formation. J. Neurosci. (1996) 16:5004–5013.
   PubMed Web of Science ®Google Scholar
• DAWSON DA, GRAHAM DI, MCCULLOCH J, et al. Anti-ischaemic efficacy of a nitric oxide synthase inhibitor and an N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischaemia. Br. J. Pharmacol. (1994) 113:247–253.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K, et al. Ebselen in acute ischaemic stroke: a placebo-controlled, double-blind clinical trial. Stroke (1998) 29:12–17.
   PubMed Web of Science ®Google Scholar
• PAUL T, ATKINS MD, PHILIP K, et al. Immediate early gene expression in response to cerebral ischaemia friend or foe Stroke (1996) 27:1682–1687.
   PubMed Web of Science ®Google Scholar
• KOKETSU N, BERLOVE DJ, MOSKOWITZ MA, et al. Pretreatment with intraventricular basic fibroblast growth factor (bFGF) decreases infarct size following focal cerebral ischemia in rats. Ann. Neurol. (1994) 35:451–457.
   PubMed Web of Science ®Google Scholar
• KAWAMATA T, ALEXIS NE, DALTON DIETRICH W, et al. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioural recovery following focal cerebral infarction in the rat. J. Cereb. Blood Flow Metab. (1996) 16:542–547.
   PubMed Web of Science ®Google Scholar
• DE VRIES HE, KUIPAR J, DE BOER AG, et al. The blood-brain barrier in neuroinflammatory diseases. Pharmacol. Rev. (1997) 49:143–155.
   PubMed Web of Science ®Google Scholar
• CLARK RK, LEE EV, FISH CJ, et al. Development of tissue damage, inflammation and resolution following stroke: an immunohistochemical and quantitiative planimetric study. Brain Res. Bull. (1992) 31:565–572.
   Web of Science ®Google Scholar
• ZHANG RL, CHOPP M, LI Y et al.: Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology (1994) 44:1747–1751.
   PubMed Web of Science ®Google Scholar
• AKOPOV SE, SIMONIAN NA, GRIGORIAN GS: Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke (1996) 27:1739–1743.
   PubMed Web of Science ®Google Scholar
• WELBOURN CRB, GOLDMAN G, PATERSON IS, et al. Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br. J. Surg. (1991) 78:651–655.
   PubMed Web of Science ®Google Scholar
• KOSTULAS N, KIVISAKK P, HUANG Y et al.: Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke (1989) 29:462–466.
   Google Scholar
• DEL ZOPPO GJ: Microvascular responses to cerebral ischemia/inflammation. Ann. NY Acad. Sci. (1997) 823:132–147.
   PubMed Web of Science ®Google Scholar
• HARLING H-P, BER EL, TSURUSHITA N, et al. E-Selectin appears in nonischemic tissue during experimental focal cerebral ischemia. Stroke (1996) 27:1386–1392.
   Web of Science ®Google Scholar
• MATSUO Y, ONODERA H, SHIGA Y et al.: Correlation between myeloperoxidase-quantified neutrophil accumulation and ischaemic brain injury in the rat: effects of neutrophil depletion. Stroke (1994) 25:1469–1475.
   PubMed Web of Science ®Google Scholar
• HARA H, FINK K, ENDRES M, et al. Attenuation of transient focal cerebral ischaemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J. Cereb. Blood Flow Metab. (1997) 17:370–375.
   PubMed Web of Science ®Google Scholar
• CLARK WM, ZIVIN JA: Anti-adhesion molecule monoclonal antibodies therapeutic potential in ischaemic stroke. CNS Drugs (1996) 2:90–99.
   Google Scholar
• POZZILLI C, LENZI GL, ARGENTINO C, et al. Imaging of leukocytic infiltration in human cerebral infarcts. Stroke (1985) 16:251–255.
   PubMed Web of Science ®Google Scholar
• SIMS MJ, HASSAL DG, BRETT S, et al. A humanized CD18 antibody can block function without cell destruction. J. Immunol. (1993) 151:2296–2308.
   PubMed Web of Science ®Google Scholar
• ZHANG ZG, CHOPP M, TANG WX, et al. Postischemic treatment (2-4 h) with anti-CD1 lb and anti-CD18 monoclonal antibodies is neuroprotective after transient (2 h) focal cerebral ischaemia in the rat. Brain Res. (1995) 698:79–85.
   PubMed Web of Science ®Google Scholar
• MACKAY K, BAILEY SJ, KING PD, et al. Neuroprotective effect of recombinant neutrophil inhibitory factor in transient focal cerebral ischaemia in the rat. Neurodegeneration (1996) 5:319–323.
   PubMedGoogle Scholar
• ANCROD STROKE STUDY INVESTIGATORS: Ancrod for the treatment of acute ischaemic brain infarction. Stroke (1994) 25:1755–1759.
   PubMed Web of Science ®Google Scholar
• DORMAN PJ, SANDERCOCK PAG: Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke (1996) 27:1507–1515.
   PubMed Web of Science ®Google Scholar
• DYKER AG, LEES KR: Duration of neuroprotective treatment for ischaemic stroke. Stroke (1998) 29:535–542.
   PubMed Web of Science ®Google Scholar
• BULLOCK R, ZAUNER A, WOODWARD J: Massive persistent release of excitatory amino acids following human occlusive stroke. Stroke (1995) 20:2187–2189.
   Google Scholar
• DU C, HU R, CSERNANSKY CA, et al. Very delayed infarction after mild focal cerebral ischaemia: a role for apoptosis J. Cereb. Blood Flow Metab. (1996) 16:195–201.
   PubMed Web of Science ®Google Scholar
• J Kriegelstein (Ed.), Medpharm, Stuttgart (1996):691–699.
   Google Scholar